Rachel Haurwitz - Caribou Biosciences CEO, CoFounder

All Insiders . USA . 
Stock . Caribou Biosciences . Stakeholders . Insider . Rachel Haurwitz
CRBU Stock  USD 1.20  0.04  3.23%   

Insider

Rachel Haurwitz is CEO, CoFounder of Caribou Biosciences
Age 39
Address 2929 7th Street, Berkeley, CA, United States, 94710
Phone510 982 6030
Webhttps://cariboubio.com

Rachel Haurwitz Latest Insider Activity

Tracking and analyzing the buying and selling activities of Rachel Haurwitz against Caribou Biosciences stock is an integral part of due diligence when investing in Caribou Biosciences. Rachel Haurwitz insider activity provides valuable insight into whether Caribou Biosciences is net buyers or sellers over its current business cycle. Note, Caribou Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Caribou Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Rachel Haurwitz over three months ago
Acquisition by Rachel Haurwitz of 10000 shares of Caribou Biosciences at 2.96 subject to Rule 16b-3
 
Rachel Haurwitz over a year ago
Acquisition by Rachel Haurwitz of 118700 shares of Caribou Biosciences subject to Rule 16b-3
 
Rachel Haurwitz over a year ago
Exercise or conversion by Rachel Haurwitz of 10000 shares of Caribou Biosciences subject to Rule 16b-3

Caribou Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.2514) % which means that it has lost $0.2514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.436) %, meaning that it created substantial loss on money invested by shareholders. Caribou Biosciences' management efficiency ratios could be used to measure how well Caribou Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.22 in 2025. Return On Capital Employed is likely to drop to -0.27 in 2025. Non Current Liabilities Total is likely to gain to about 32.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 23 M in 2025.
Caribou Biosciences currently holds 27.11 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Caribou Biosciences has a current ratio of 11.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Caribou Biosciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Keith MDPrime Medicine, Common
71
Allison DorvalVerve Therapeutics
48
Andrew MayIntellia Therapeutics
N/A
Nitin SoodAdaptive Biotechnologies Corp
N/A
Shanna PeekSana Biotechnology
N/A
Mark AdamsAdaptive Biotechnologies Corp
57
Rodger MDCrispr Therapeutics AG
57
Emmanuelle CharpentierCrispr Therapeutics AG
N/A
Christopher CarlsonAdaptive Biotechnologies Corp
N/A
Brendan MBACrispr Therapeutics AG
48
Anthony MDVerve Therapeutics
N/A
Giuseppe CiaramellaBeam Therapeutics
56
Alexis KomorBeam Therapeutics
N/A
MS MBAFate Therapeutics
N/A
Mark ShearmanEditas Medicine
64
Craig MelloCrispr Therapeutics AG
N/A
MD MPHVerve Therapeutics
N/A
Chad CowanCrispr Therapeutics AG
N/A
Nicole GaudelliBeam Therapeutics
N/A
Lawrence KleinCrispr Therapeutics AG
42
Edward IIIFate Therapeutics
48
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Caribou Biosciences (CRBU) is traded on NASDAQ Exchange in USA. It is located in 2929 7th Street, Berkeley, CA, United States, 94710 and employs 158 people. Caribou Biosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-0.44
Return On Asset-0.25

Caribou Biosciences Leadership Team

Elected by the shareholders, the Caribou Biosciences' board of directors comprises two types of representatives: Caribou Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caribou. The board's role is to monitor Caribou Biosciences' management team and ensure that shareholders' interests are well served. Caribou Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caribou Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sriram MBA, Chief Officer
Amy CFA, Vice Communications
Cindy Hayashi, VP HR
Ryan Fischesser, Interim Controller
Jason MBA, Chief Officer
JD Esq, Chief Secretary
Timothy MBA, Chief Officer
Reigin Zawadzki, Chief Officer
Syed MD, Chief Officer
Rachel Haurwitz, CEO, CoFounder
Steven Kanner, Chief Officer
Ruhi MBA, Chief Officer
Justin Skoble, VP Operations
Daniel Poon, Vice Technology

Caribou Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caribou Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.44
Return On Asset-0.25
Operating Margin(16.67) %
Current Valuation(88.8 M)
Shares Outstanding90.55 M
Shares Owned By Insiders10.14 %
Shares Owned By Institutions63.28 %
Number Of Shares Shorted8.86 M
Price To Book0.40 X
Price To Sales9.79 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY